Plasma levels of 15d-PGJ are not altered in multiple sclerosis.
BACKGROUND
The 15-deoxi delta prostaglandin J(2) (15d-PGJ(2)) is a peroxisome proliferator-activated receptor-gamma agonist with potent anti-inflammatory properties. It has been suggested that 15d-PGJ(2) may modulate multiple sclerosis (MS).


METHODS
Here, we investigated the plasma levels of 15d-PGJ(2) by enzyme-linked immunoassay in 28 healthy controls and 140 MS patients [30 patients with primary-progressive MS, 28 patients with secondary-progressive MS, and 82 patients with relapsing-remitting MS (28 patients during clinical remission, 25 patients during relapse, and 29 treated with interferon-beta - IFN-beta)].


RESULTS
Levels of 15d-PGJ(2) were similar between healthy controls and untreated MS patients with different clinical courses of the disease. Treatment with IFN-beta had no effect on levels of 15d-PGJ(2).


CONCLUSIONS
Although these findings suggest that 15d-PGJ(2) is not involved in the acute or chronic phases of the disease, further studies measuring 15d-PGJ(2) in cerebrospinal fluid samples are needed before excluding a role of 15d-PGJ(2) in MS.
Comabella
M
M
Unitat de Neuroimmunologia Clínica, CEM-Cat, Hospital Universitari Vall d 'Hebron (HUVH), Barcelona, Spain. mcomabel@ir.vhebron.net
Pradillo
J M
JM
Fernández
M
M
Río
J
J
Lizasoain
I
I
Julià
E
E
Moro
M A
MA
Sastre-Garriga
J
J
Montalban
X
X
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood* / Q000188:drug therapy; D015230:Prostaglandin D2 / Q000031:analogs & derivatives* / Q000097:blood
C477819:15-deoxyprostaglandin J2; D000893:Anti-Inflammatory Agents; D016899:Interferon-beta; D015230:Prostaglandin D2